<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598750</url>
  </required_header>
  <id_info>
    <org_study_id>TRF15483</org_study_id>
    <secondary_id>2P01HL046925-21A1</secondary_id>
    <nct_id>NCT04598750</nct_id>
  </id_info>
  <brief_title>The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia</brief_title>
  <acronym>NEOHAT-2</acronym>
  <official_title>The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Stockholm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Society of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational study designed to evaluate Immature Platelet Fraction or&#xD;
      Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro&#xD;
      bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to&#xD;
      the Neonatal Intensive Care Unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thrombocytopenia is a known risk factor for clinically significant bleeding in neonates.&#xD;
      However, there is a poor correlation between degree of thrombocytopenia and bleeding risk. A&#xD;
      better marker of bleeding risk suitable for use in neonates could help physicians more&#xD;
      accurately determine the risk/benefit ratio of platelet transfusions, guiding platelet&#xD;
      transfusion decisions, and potentially protecting vulnerable infants from exposure to&#xD;
      unnecessary transfusion-related risks. The investigators recently found that the Platelet&#xD;
      Function Analyzer (PFA) Closure Time-Collagen/ADP (CT-ADP) was a better marker of bleeding&#xD;
      than the platelet count in preterm neonates. However, the CT-ADP requires 0.8 mL blood&#xD;
      limiting its potential widespread use. The Immature Platelet Fraction (IPF) is a new&#xD;
      laboratory marker measuring the % newly released and more active platelets, measured from the&#xD;
      same sample as the platelet count. This is a prospective observational study designed to&#xD;
      evaluate IPF as marker of bleeding risk in thrombocytopenic neonates admitted to the Neonatal&#xD;
      Intensive Care Unit, compared to platelet counts alone. And also, to validate the previously&#xD;
      found association between PFA-100/200 CT-ADP and bleeding in a bigger cohort, to compare the&#xD;
      IPF with the PFA-100/200 CT-ADP as bleeding predictors and to assess whether the PFA-100/200&#xD;
      CT-ADP combined with the IPF is able to predict bleeding in thrombocytopenic preterm&#xD;
      neonates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NeoBAT score</measure>
    <time_frame>24 hours</time_frame>
    <description>NeoBAT scores will include any bleeding since the last platelet count or over the prior 24 hours, whichever is shortest. This will serve to correlate bleeding scores (NeoBAT) with platelet counts, IPF% and IPC, PFA-100/200 CT-ADP, and to quantify changes in response to platelet transfusions. The scale is 1 to 4 with 1 being Minor Hemorrhage and 4 being Severe Hemorrhage.</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Neonatal Thrombocytopenia</condition>
  <condition>Bleeding</condition>
  <eligibility>
    <study_pop>
      <textblock>
        - Infants will be eligible for study if they have a gestational age &lt;32 weeks and a birth&#xD;
        weight ≥500 grams; and have a platelet count &lt;100 x 109/L.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a gestational age &lt;32 weeks and a birth weight ≥500 grams;&#xD;
&#xD;
          -  Have a platelet count &lt;100 x 109/L; and&#xD;
&#xD;
          -  Have a parent/guardian willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are not expected to survive for &gt;24 hours by the Attending Neonatologist;&#xD;
&#xD;
          -  Are thought to have a familial thrombocytopenia or platelet dysfunction, based on&#xD;
             family history or clinical presentation (associated congenital malformations, platelet&#xD;
             morphology).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emöke Deschmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Christensen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Utah Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emöke Deschmann, MD, PhD</last_name>
    <phone>+46 73 539 5575</phone>
    <email>emoke.deschmann@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martha Sola-Visner, MD</last_name>
    <phone>617-919-4845</phone>
    <email>martha.sola-visner@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Sola-Visner, MD</last_name>
      <email>martha.sola-visner@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martha Sola-Visner, MD</last_name>
      <email>martha.sola-visner@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Christensen, MD</last_name>
      <email>robert.christensen@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utah Valley Hospital</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Christensen, MD</last_name>
      <email>robert.christensen@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wes Onland, MD, PhD</last_name>
      <email>w.onland@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Lopriore, MD, PhD</last_name>
      <email>e.lopriore@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge campus</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emoke Deschmann, MD PhD MMSc</last_name>
      <phone>+46735395575</phone>
      <email>emoke.deschmann@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna campus, Astrid Lindgren Children's Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emoke Deschmann, MD PhD MMSc</last_name>
      <phone>+46735395575</phone>
      <email>emoke.deschmann@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Emoke Deschmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Thrombocytopenia, Neonatal Alloimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

